GleamWall
中文EN

PEPG PepGen Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1835597 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY21.6%
TTM EPS YoY72.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-55.1%
ROA-46.1%
ROIC (approx.)-121.4%
Asset turnover—

Leverage & solvency

Liabilities / assets19.3%
Debt / equity0.00x
Current ratio8.70x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.86x
Accruals ratio-6.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$71.04M$76.48M
SG&A expense$22.57M$21.26M
Operating income-$93.61M-$97.74M
Pretax income-$89.61M-$90.60M
Income tax$48,865-$617,000
Net income-$89.66M-$89.98M
EBITDA-$92.21M-$96.24M
EPS (basic)-2.12-2.85
EPS (diluted)-2.12-2.85
Weighted avg. shares (diluted)42.22M31.58M
Balance sheet
Cash & equivalents$60.51M$49.42M
Short-term investments$87.94M$70.77M
Current assets$150.96M$123.76M
PP&E, net$1.90M$3.72M
Total assets$173.91M$150.88M
Current liabilities$12.65M$16.70M
Total liabilities$26.46M$32.26M
Shareholders' equity$147.44M$118.62M
Shares outstanding68.87M32.62M
Cash flow statement
Operating cash flow-$81.64M-$82.37M
Capital expenditure$264,000$497,000
Free cash flow-$81.90M-$82.87M
Investing cash flow-$15.23M-$37.67M
Financing cash flow$107.98M$88.75M
Depreciation & amortization$1.40M$1.50M
Stock-based compensation$10.61M$11.46M

Free plan shows the latest 2 periods; Pro shows all 5 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.